The clinical evidence base for spinal manipulative therapy in LBP is anchored by multiple high-quality meta-analyses and major guideline recommendations. For acute LBP, Paige et al. (JAMA 2017) synthesized 26 randomized controlled trials and found moderate-quality evidence that SMT was associated with modest improvements in pain — a pooled mean improvement of −9.95 on a 100-mm visual analog scale — and function, with a standardized mean difference of −0.39 for disability outcomes. Serious adverse events were not reported in any included trial, and minor transient effects such as local soreness resolved within 24–48 hours. For chronic LBP, Rubinstein et al. (BMJ 2019) analyzed 47 randomized trials involving over 9,200 patients and found high-quality evidence that SMT produced effects broadly similar to other recommended first-line therapies — including exercise and supervised physical therapy — while outperforming non-recommended comparators. The American College of Physicians guideline (Qaseem et al., Ann Intern Med 2017) recommends that clinicians and patients initially select non-pharmacological treatment for both acute and chronic LBP, explicitly listing spinal manipulation among recommended options. The Lancet Low Back Pain Series (Foster et al. 2018) reinforces this position, recommending a biopsychosocial framework with initial non-pharmacological, non-surgical care for the vast majority of patients. These guideline recommendations position chiropractic SMT as a first-line conservative option — not as a cure or universally superior treatment, but as one well-supported modality within a comprehensive, patient-centered approach.

In the largest pragmatic comparative effectiveness trial of chiropractic care for LBP, Goertz et al. (JAMA Netw Open 2018) randomized 750 active-duty military service members and found that adding chiropractic care to usual medical care produced moderate improvements in pain intensity — a mean difference of −1.1 on the 0–10 numeric rating scale — along with improvements in disability and patient satisfaction at six weeks, and a 37% reduction in the odds of using pain medication compared to the usual care group. Haas et al. (Spine J 2014) conducted a dose-response randomized trial of 400 patients and found a treatment response that saturated at approximately 12 sessions over six weeks, with 50% of patients in the 12-session group achieving at least 50% pain improvement at 12 weeks. Gains were sustained at one-year follow-up, and additional sessions beyond 12 did not produce significantly greater benefit — providing practical dosing guidance that supports time-limited, goal-directed care rather than open-ended treatment.
Scientific integrity requires acknowledging null findings alongside positive ones. Hancock et al. (Lancet 2007) randomized 240 patients with acute LBP in a 2×2 factorial design and found that adding SMT to recommended first-line care — advice plus paracetamol — did not speed recovery compared to placebo conditions. This important null result suggests that when adequate first-line care is already provided, the incremental benefit of adding SMT for uncomplicated acute LBP may be negligible, consistent with the natural history of most acute episodes toward resolution. More recently, Gevers-Montoro et al. (J Pain 2024) conducted a placebo-controlled, double-blind randomized trial in chronic primary LBP and found that a structured SMT course produced clinically significant pain reduction compared to a convincingly blinded sham intervention, with improvements accompanied by reductions in segmental mechanical hyperalgesia and pain catastrophizing — suggesting engagement of both peripheral and central mechanisms. This mechanistically-correlated placebo-controlled trial is particularly important because it addresses the longstanding challenge of adequate blinding in manual therapy research and provides evidence that SMT's effects in chronic LBP are not entirely attributable to nonspecific therapeutic factors.

Amid the ongoing opioid crisis, observational evidence increasingly suggests that access to chiropractic care may be associated with reduced opioid exposure in LBP populations. Whedon et al. (JACM 2018) found in a retrospective cohort of 6,868 LBP patients that adults receiving chiropractic care were 55% less likely to fill an opioid prescription compared to non-recipients. A separate large claims-based analysis reported chiropractic users had approximately 64% lower odds of receiving an opioid prescription for spine pain. These findings carry significant public health relevance, though they are observational associations rather than causal findings — patients who choose chiropractic care likely differ from those who do not in ways that confound the comparison, and randomized evidence on opioid outcomes in chiropractic trials remains limited. The association nonetheless supports further investigation into chiropractic-first pathways as a strategy for reducing opioid prescribing in primary care settings for LBP.